Glenmark Pharma reports Q3 FY 2022-23 revenue growth of 9.2%; PAT growth of 21.3%
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY